During the summer of 2020, a handful of major drugmakers caused upheaval in the pharmaceutical industry when they announced changes to their participation in the 340B Drug Pricing Program, eliciting condemnation from providers and their allies.
The announced changes primarily affect contract pharmacies, which play a unique role for providers and patients in rural communities where healthcare access is already a significant issue. While drugmakers’ concerns about compliance challenges at contract pharmacies are not unfounded, cutting off contract pharmacies may produce harmful results for vulnerable patients and the health of rural communities.
- Recent changes to drugmakers’ participation in 340B Drug Pricing Program
- The role of contract pharmacies in 340B
- The consequences of cutting out contract pharmacies
Download our whitepaper below to learn more.